Mycophenolate mofetil and Multifocal micronodular pneumocyte hyperplasia - a phase IV clinical study of FDA data

Summary:

Multifocal micronodular pneumocyte hyperplasia is reported as a side effect among people who take Mycophenolate mofetil (mycophenolate mofetil), especially for people who are female, 40-49 old, also take Cyclophosphamide, and have Breast cancer.

The phase IV clinical study analyzes which people have Multifocal micronodular pneumocyte hyperplasia when taking Mycophenolate mofetil. It is created by eHealthMe based on reports of 93,176 people who have side effects when taking Mycophenolate mofetil from the FDA, and is updated regularly.

What is Mycophenolate mofetil?

Mycophenolate mofetil has active ingredients of mycophenolate mofetil. It is often used in myasthenia gravis. eHealthMe is studying from 93,461 Mycophenolate mofetil users. Check the latest studies of Mycophenolate mofetil.

What is Multifocal micronodular pneumocyte hyperplasia?

Multifocal micronodular pneumocyte hyperplasia is found to be associated with 4 drugs and 24 conditions by eHealthMe. Check the latest studies of Multifocal micronodular pneumocyte hyperplasia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

93,176 people reported to have side effects when taking Mycophenolate mofetil.
Among them, 26 people (0.03%) have Multifocal micronodular pneumocyte hyperplasia.

Could Mycophenolate mofetil cause Multifocal micronodular pneumocyte hyperplasia?

Among these 26 people:

What is the gender of people who have Multifocal micronodular pneumocyte hyperplasia when taking Mycophenolate mofetil? *

female: 100 %
male: 0.0 %

What is the age of people who have Multifocal micronodular pneumocyte hyperplasia when taking Mycophenolate mofetil? *

What are other drugs people take besides Mycophenolate mofetil? *

Prednisone: 1 person, 3.85%
Herceptin: 1 person, 3.85%
Docetaxel: 1 person, 3.85%
Cyclophosphamide: 1 person, 3.85%

What are other side effects people have besides Multifocal micronodular pneumocyte hyperplasia? *

Therapeutic Response Decreased (less preventive response): 26 people, 100.00%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 26 people, 100.00%
Pulmonary Oedema (fluid accumulation in the lungs): 26 people, 100.00%
Organising Pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue): 26 people, 100.00%
Computerised Tomogram Thorax Abnormal: 26 people, 100.00%
Bronchial Polyp: 26 people, 100.00%
Biopsy Lung Abnormal: 26 people, 100.00%

What are the existing conditions these people have? *

Organising Pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue): 26 people, 100.00%
Breast Cancer: 26 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mycophenolate mofetil and have Multifocal micronodular pneumocyte hyperplasia?

- Check whether Multifocal micronodular pneumocyte hyperplasia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mycophenolate mofetil:

Mycophenolate mofetil (93,461 reports)

Multifocal micronodular pneumocyte hyperplasia treatments and more:

Multifocal micronodular pneumocyte hyperplasia (48 reports)

How severe was Multifocal micronodular pneumocyte hyperplasia and when was it recovered:

Multifocal micronodular pneumocyte hyperplasia in Mycophenolate mofetil

Expand to all the drugs that have ingredients of mycophenolate mofetil:

Multifocal micronodular pneumocyte hyperplasia and drugs with ingredients of mycophenolate mofetil (31 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mycophenolate mofetil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multifocal micronodular pneumocyte hyperplasia:

Multifocal micronodular pneumocyte hyperplasia (4 drugs)

Browse all the conditions that are associated with Multifocal micronodular pneumocyte hyperplasia:

Multifocal micronodular pneumocyte hyperplasia (24 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil (the active ingredients of Mycophenolate mofetil) and Mycophenolate mofetil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.